Evolving mRNA vaccines are shifting beyond infectious diseases to focus on personalized cancer therapies, enhanced delivery mechanisms, and next-generation, dose-sparing technologies. Key developments indicate a move toward more stable, potent, and broadly applicable mRNA platforms